A Phase III trial has demonstrated that patients with advanced Stage III/IV classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.
News
![Voices of Hodgkin’s Blog](/wp-content/themes/hodgkins/img/hero-yellow.jpg)
![Voices of Hodgkin’s Blog](/wp-content/themes/hodgkins/img/hero-default.jpg)